Covid-19 vaccine trial in UK has 80% chance of success: Scientist
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Sunday
January 29, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
SUNDAY, JANUARY 29, 2023
Covid-19 vaccine trial in UK has 80% chance of success: Scientist

Coronavirus chronicle

TBS Report
23 April, 2020, 02:00 pm
Last modified: 23 April, 2020, 02:06 pm

Related News

  • Bank of England set to hike to 4% as rate peak looms
  • UK says 200 asylum-seeking children missing, some aged under 16
  • Britain and EU unlikely to change Brexit deal much, despite issues
  • US, EU, UK impose new sanctions on Iran over protest crackdown
  • UK says it still wants Ukraine to get German-made tanks

Covid-19 vaccine trial in UK has 80% chance of success: Scientist

The race to develop an effective vaccine against the novel coronavirus gathered pace this week, as clinical trials on humans were approved in Germany and launched in the UK

TBS Report
23 April, 2020, 02:00 pm
Last modified: 23 April, 2020, 02:06 pm
This scanning electron microscope image shows SARS-CoV-2 (round blue objects), also known as novel coronavirus, the virus that causes COVID-19, emerging from the surface of cells cultured in the lab which was isolated from a patient in US/Reuters
This scanning electron microscope image shows SARS-CoV-2 (round blue objects), also known as novel coronavirus, the virus that causes COVID-19, emerging from the surface of cells cultured in the lab which was isolated from a patient in US/Reuters

The Covid-19 vaccine developed by scientists at the University of Oxford, is expected to have an 80% chance of success.

In Britain, volunteers in a trial at the University of Oxford are set to be given on Thursday the first dose of a potential vaccine based on a virus found in chimpanzees.

The race to develop an effective vaccine against the novel coronavirus gathered pace this week, as clinical trials on humans were approved in Germany and launched in the UK, reported Hindustan Times.

Though there are now around 150 development projects worldwide, the German and British plans are among only five clinical trials on humans which have been approved across the globe.

Meanwhile on Wednesday, German regulatory body PEI green-lighted the country's first trials on human volunteers for a vaccine developed by German firm Biontech and US giant Pfizer.

The Oxford trial, run by the university's Jenner Institute, will involve 510 volunteers aged between 18 and 55 in the first phase.

Research director Professor Sarah Gilbert estimated that it has around an 80 percent chance of being successful.

The institute aims to develop a million doses of the vaccine by September, so as to distribute it as quickly as possible after approval.

The Oxford trial is part of a nationwide effort in the UK which since Friday has been spearheaded by a government taskforce.

In Germany, meanwhile, the PEI said its approval of the Biontech trial marked a "significant step" in making a vaccine "available as soon as possible".

In the first phase, it will see "200 healthy volunteers aged between 18 and 55 years" vaccinated with variants of the vaccine, while the second phase could see the inclusion of volunteers who belonged to high-risk groups.

On Wednesday, Biontech CEO Ugur Sahin told a press conference that tests would begin "at the end of April".

He added that the firm expected to have collected first data by "the end of June or beginning of July".

Biontech also said that they and Pfizer hoped to gain regulatory approval soon to test the same vaccine candidate in the US.

The PEI meanwhile claimed that "further clinical trials of COVID-19 vaccine candidates will start in Germany in the next few months".

There are currently no approved vaccines or medication for the COVID-19 disease, which has killed more than 170,000 people worldwide and infected more than two million.

Experts estimate that it will take at least 12 to 18 months to develop a new vaccine.

Last week, UN Secretary-General Antonio Guterres said a vaccine was the only thing to return "normalcy" to the world, and called for development projects to be accelerated.

A UN resolution adopted on Monday, meanwhile, called for "equitable, efficient and timely" access to any vaccine that might be developed.

Aside from Biontech and Oxford, three other clinical trials on humans have been approved worldwide since mid-March, with Chinese and US developers among the first to move.

Beijing approved the first trial for a vaccine developed by the military-backed Academy of Military Medical Sciences and Hong Kong-listed biotech firm CanSino Bio on March 16.

That day the US drug developer Moderna said it had begun human tests for their vaccine with the US National Institutes of Health.

Another US lab, San Diego-based Inovio Pharmaceuticals, began first phase human trials on April 6.

Yet while Biontech hailed what it called a "global development program" on Wednesday, the search for a vaccine has also been a cause of friction between countries.

Last month a newspaper report alleged that the US had attempted to buy exclusive rights to vaccine research being carried out by CureVac, another German firm.

Though CureVac and US officials dismissed it as unfounded, the newspaper report caused outrage in Berlin, and prompted Economy Minister Peter Altmaier to declare that "Germany is not for sale".

Top News

Coronavirus / Vaccination / UK

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Import slowdown to affect economic growth: ADB country head
    Import slowdown to affect economic growth: ADB country head
  • Photo: Collected
    Foreign loan pledges fall 60% in H1  
  • Debapriya Bhattacharya. Illustration: TBS
    Business leaders’ role in corruption is also questionable: Debapriya

MOST VIEWED

  • FIKE PHOTO: Medical staff moves a patient into a fever clinic at a hospital, as coronavirus disease (COVID-19) outbreaks continue in Shanghai, China, December 19, 2022. REUTERS/Aly Song
    China approves two domestically developed Covid drugs
  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs
  • Photo: Collected
    India launches world’s 1st intranasal Covid vaccine
  • A vial of the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants is pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier
    US CDC still looking at potential stroke risk from Pfizer bivalent Covid shot
  •  A medical worker checks the IV drip treatment of a patient lying on a bed in the emergency department of a hospital, amid the coronavirus disease (COVID-19) outbreak in Shanghai, China, January 5, 2023. REUTERS/Staff
    China says Covid deaths down by nearly 80 percent
  • Sean Bagley, 14, receives the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier
    Updated Covid vaccines prevented illness from latest variants -CDC

Related News

  • Bank of England set to hike to 4% as rate peak looms
  • UK says 200 asylum-seeking children missing, some aged under 16
  • Britain and EU unlikely to change Brexit deal much, despite issues
  • US, EU, UK impose new sanctions on Iran over protest crackdown
  • UK says it still wants Ukraine to get German-made tanks

Features

Nandita Sharmin's journey to give organic skincare a new identity

Nandita Sharmin's journey to give organic skincare a new identity

9h | Mode
Illustration: TBS

'The silver lining is that the worst is sort of behind us': Hamid Rashid, UN economist

12h | Panorama
Photo: Bloomberg

BuzzFeed and AI are a match made in fad city

11h | Panorama
Snipe in flight. Photo: Enam Ul Haque

Baikka Beel: 'A world where snipe work late'

1d | Panorama

More Videos from TBS

Sarika Sabrin is waiting for a good film

Sarika Sabrin is waiting for a good film

2h | TBS Entertainment
Take your football game to the next level at Next Level academy

Take your football game to the next level at Next Level academy

3h | TBS SPORTS
“Investments risky without consistent policy, reliable data”- SK Bashir Uddin

“Investments risky without consistent policy, reliable data”- SK Bashir Uddin

5h | TBS Round Table
What does Shahrukh has in his 770 million dollar property?

What does Shahrukh has in his 770 million dollar property?

1d | TBS Entertainment

Most Read

1
Picture: Collected
Bangladesh

US Embassy condemns recent incidents of visa fraud

2
Illustration: TBS
Banking

16 banks at risk of capital shortfall if top 3 borrowers default

3
Photo: Collected
Splash

Hansal Mehta responds as Twitter user calls him 'shameless' for making Faraaz

4
A frozen Beyond Burger plant-based patty. Photographer: AKIRA for Bloomberg Businessweek
Bloomberg Special

Fake meat was supposed to save the world. It became just another fad

5
Bapex calls candidates for job test 9 years after advert!
Bangladesh

Bapex calls candidates for job test 9 years after advert!

6
Representational Image
Banking

Cash-strapped Islami, Al-Arafah and National turn to Sonali Bank for costly fund

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]